# References

> References — Metabolic & Weight Research Peptides Literature — Private Label Peptide — The full numbered source list for this Metabolic & Weight research peptides review: peer-reviewed trials, meta-analyses and reference monographs on tirzepatide, semaglutide, tesamorelin and MOTS-c.

**METABOLIC & WEIGHT RESEARCH / SOURCES**

Every source cited across the four compound entries, the comparison and the FAQ, listed once and numbered consistently throughout.

## The source list

The list below aggregates the cited literature for all four compounds reviewed on this desk. Each entry gives authors, title, journal and year, with a digital object identifier and a PubMed or NCBI link where one exists. A source is listed once and referred to by its number everywhere on the site, so the same figure carries the same reference on every page.

Where a source is a systematic review, a meta-analysis or a clinical reference monograph rather than a primary trial report, that is visible in the title. The list is the complete numbered source set used by this digest; findings whose supporting publications fall outside the composed set are discussed only qualitatively and are not assigned substitute citations.

## References

[1] Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40353578/
[2] Farzam K, Patel P. Tirzepatide (StatPearls). StatPearls [Internet], NCBI Bookshelf. 2024. https://www.ncbi.nlm.nih.gov/books/NBK585056/
[3] Zeng Q, et al. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023. https://pubmed.ncbi.nlm.nih.gov/37908750/
[4] Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. https://pubmed.ncbi.nlm.nih.gov/35658024/
[5] Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021. https://pubmed.ncbi.nlm.nih.gov/34170647/
[6] Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020. https://pubmed.ncbi.nlm.nih.gov/32730231/
[7] Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018. https://pubmed.ncbi.nlm.nih.gov/30473097/
[8] Perkovic V, et al. (FLOW Trial Committees and Investigators). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024. https://pubmed.ncbi.nlm.nih.gov/38785209/
[9] Lincoff AM, et al. (SELECT Trial Investigators). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. https://pubmed.ncbi.nlm.nih.gov/37952131/
[10] Wilding JPH, et al. (STEP 1 Study Group). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/
[11] Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021. https://pubmed.ncbi.nlm.nih.gov/34305810/
[12] Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity Research & Clinical Practice. 2026;20(1):2-12. https://pubmed.ncbi.nlm.nih.gov/41545261/
[13] National Institute of Diabetes and Digestive and Kidney Diseases (LiverTox). Tesamorelin - LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf (NIH). 2018. https://www.ncbi.nlm.nih.gov/books/NBK548730/
[14] Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. https://pubmed.ncbi.nlm.nih.gov/25038357/
[15] Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. Journal of Clinical Endocrinology and Metabolism. 2011;96(1):150-158. https://pubmed.ncbi.nlm.nih.gov/20943777/
[16] Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. https://pubmed.ncbi.nlm.nih.gov/18690162/
[17] Kumagai H, Kim SJ, Miller B, et al. MOTS-c modulates skeletal muscle function by directly binding and activating CK2. iScience. 2024;27(11):111212. https://pubmed.ncbi.nlm.nih.gov/39559755/
[18] Bolignano D, Greco M, Presta P, Duni A, et al. The Mitochondrial-Derived Peptide MOTS-c May Refine Mortality and Cardiovascular Risk Prediction in Chronic Hemodialysis Patients: A Multicenter Cohort Study. Blood Purification. 2024;53(10):824-837. https://pubmed.ncbi.nlm.nih.gov/39111290/
[19] Wan W, Zhang L, Lin Y, Rao X, Wang X, Hua F, Ying J. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. Journal of Translational Medicine. 2023;21(1):36. https://pubmed.ncbi.nlm.nih.gov/36670507/
[20] Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12(1):470. https://pubmed.ncbi.nlm.nih.gov/33473109/
[21] Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metabolism. 2018;28(3):516-524.e7. https://pubmed.ncbi.nlm.nih.gov/29983246/

---

Private Label Peptide is a review of published metabolic-peptide research that keeps the instrument in view — what each study weighed, scanned or only estimated, and in which population — and it prescribes nothing, dispenses nothing and supplies nothing.